{"id":"placebo-to-romosozumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Cardiovascular events (including myocardial infarction and stroke)"}]},"_chembl":{"chemblId":"CHEMBL2107874","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sclerostin is produced by osteocytes and suppresses the Wnt/β-catenin signaling pathway, which is essential for osteoblast activity and bone formation. By blocking sclerostin, romosozumab enhances osteoblast function and bone turnover, leading to rapid increases in bone mineral density. This mechanism is distinct from traditional antiresorptive agents and provides both bone formation and antiresorptive effects.","oneSentence":"Romosozumab is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation, thereby increasing bone mineral density and reducing fracture risk.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:52.242Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postmenopausal osteoporosis in women at high risk of fracture"},{"name":"Osteoporosis in men at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT06533865","phase":"PHASE3","title":"Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-03-19","conditions":"FHA (Functional Hypothalamic Amenorrhea)","enrollment":114},{"nctId":"NCT06973109","phase":"PHASE2","title":"Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Nitin Agarwal","startDate":"2026-03-20","conditions":"Osteoporosis, Post-menopausal","enrollment":36},{"nctId":"NCT05058976","phase":"PHASE4","title":"Romosozumab Use to Build Skeletal Integrity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Susan L. Greenspan","startDate":"2021-09-15","conditions":"Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture","enrollment":184},{"nctId":"NCT04232657","phase":"PHASE2","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-03-01","conditions":"Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI","enrollment":36},{"nctId":"NCT01631214","phase":"PHASE3","title":"Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-05-04","conditions":"Postmenopausal Women With Osteoporosis","enrollment":4093},{"nctId":"NCT05067335","phase":"PHASE3","title":"A Study to Test the Efficacy, Safety and Tolerability of Romosozumab Treatment in Postmenopausal Chinese Women With Osteoporosis","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2021-10-21","conditions":"Osteoporosis","enrollment":327},{"nctId":"NCT01575834","phase":"PHASE3","title":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-15","conditions":"Postmenopausal Osteoporosis","enrollment":7180},{"nctId":"NCT01825785","phase":"PHASE1","title":"A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-11-14","conditions":"Postmenopausal, Osteopenia","enrollment":48},{"nctId":"NCT00896532","phase":"PHASE2","title":"Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-06-03","conditions":"Low Bone Mineral Density, Postmenopausal Osteoporosis","enrollment":419},{"nctId":"NCT01081678","phase":"PHASE2","title":"Study To Assess FRacTure Healing With SclerosTin Antibody - Hip","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-06-20","conditions":"Fracture Healing","enrollment":332},{"nctId":"NCT02791516","phase":"PHASE3","title":"A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-01-16","conditions":"Postmenopausal Osteoporosis","enrollment":67},{"nctId":"NCT01101061","phase":"PHASE1","title":"A Single-dose Study Evaluating Romosozumab (AMG 785) in Healthy Postmenopausal Japanese and Non-Japanese Women","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-05-03","conditions":"Osteopenia","enrollment":31},{"nctId":"NCT00950950","phase":"PHASE1","title":"A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-08-18","conditions":"Osteopenia","enrollment":24},{"nctId":"NCT01059435","phase":"PHASE1","title":"A First-in-human Study Evaluating Romosozumab (AMG 785) in Healthy Men and Postmenopausal Women","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-13","conditions":"Osteopenia","enrollment":74},{"nctId":"NCT02186171","phase":"PHASE3","title":"A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2014-06-16","conditions":"Osteoporosis in Men","enrollment":245},{"nctId":"NCT01992159","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-10-12","conditions":"Postmenopausal Osteoporosis (PMO)","enrollment":252},{"nctId":"NCT02016716","phase":"PHASE3","title":"A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-12-03","conditions":"Postmenopausal Osteoporosis","enrollment":294}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":91,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Romosozumab","genericName":"Placebo to Romosozumab","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Romosozumab is a monoclonal antibody that inhibits sclerostin, a negative regulator of bone formation, thereby increasing bone mineral density and reducing fracture risk. Used for Postmenopausal osteoporosis in women at high risk of fracture, Osteoporosis in men at high risk of fracture.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}